Pediatric VNS Study Supports Cyberonics’ Focus On Epilepsy Growth Strategy
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics may expand use of its vagus nerve stimulation (VNS) therapy device to children with drug-resistant epilepsy aged 12 and younger, following positive results from a small study conducted by the Children's Hospital at The Cleveland Clinic